Shattuck Labs, Inc.
STTK
$-0.06
Change (1 day)
$11.76
Year High
$1.15
Year Low
Categories
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
P/S ratio for Shattuck Labs, Inc. (STTK)
P/S ratio as of 2023: 183.31
According to Shattuck Labs, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 183.31. At the end of 2022 the company had a P/S ratio of 149.50.
P/S ratio history for Shattuck Labs, Inc. from 2018 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 183.31 |
| 2022 | 149.50 |
| 2021 | 11.92 |
| 2020 | 220.36 |
| 2019 | 81.70 |
| 2018 | 12.97 |